Glaxo Lures Top Pfizer Scientist to Lead Vaccines Research

Bloomberg2021-11-30

Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot Drugmaker is trying to regain position as top vaccine producer GlaxoSmithKline Plc lured a senior Pfizer Inc. scientist who helped ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

SHUAT
2021-11-30
SHUAT
Wow
Jeromelim
2021-11-30
Jeromelim
that’s positive thinking
Jimmyboy
2021-11-30
Jimmyboy
Please like

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1157221915?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-30 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157221915","market":"us","top_or_hot":-1,"title":"Glaxo Lures Top Pfizer Scientist to Lead Vaccines Research","media":"Bloomberg","content":"<div>\n<p>Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain position as top vaccine producer\n\nGlaxoSmithKline Plc lured a senior Pfizer Inc. scientist who helped ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp\">网页链接</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo Lures Top Pfizer Scientist to Lead Vaccines Research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo Lures Top Pfizer Scientist to Lead Vaccines Research\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain position as top vaccine producer\n\nGlaxoSmithKline Plc lured a senior Pfizer Inc. scientist who helped ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp","article_id":"1157221915","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157221915","pubTimestamp":1638278781,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain positio","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞","GSK":"葛兰素史克"},"translate_title":"葛兰素引诱辉瑞顶尖科学家领导疫苗研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":0.9,"PFE":0.9},"content_text":"Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain position as top vaccine producer\n\nGlaxoSmithKline Plc lured a senior Pfizer Inc. scientist who helped develop the U.S. pharma company’s Covid shot to oversee vaccines research and development as it takes on increased competition in the field.\nPhil Dormitzer is set to join Glaxo as global head of vaccines R&D, the British pharma company said in a statement Tuesday. As chief scientific officer of RNA and viral vaccines at Pfizer, he worked on respiratory syncytial virus and influenza shots, as well as the RNA-based Covid vaccine with BioNTech SE.\nGlaxo was the number-one producer of vaccines before the pandemic but failed to successfully develop its own Covid shot while Pfizer,Moderna Inc. and U.K. rival AstraZeneca Plc managed to do so. The pharma company is now seeking to capitalize on technologies such as messenger RNA and ensure it’s a dominant player beyond the pandemic.\nActivist investment firm Elliott Investment Management has been agitating for changes at the drugmaker since taking a multi-billion-dollar stake in the company and publicly disagreeing with some parts of its strategy.\nAn experimental Covid vaccine Glaxo has been developing with Sanofi has suffered months of delays, but could become available next year if a late-stage trial is successful.\nPfizer expects $36 billion in revenue from its Covid vaccine this year.\nDormitzer’s appointment comes as Glaxo prepares for a separation in mid-2022 that will leave a standalone pharma and vaccines company. The new vaccines executive, who will be based in the Boston area, previously worked at Novartis AG, where he was involved in the Swiss drugmaker’s response to the H1N1 influenza pandemic, among other roles.\n“Phil’s scientific expertise and significant experience with key innovative technologies, such as mRNA, structure-based antigen design and synthetic biology, will be key to ensuring we remain a leader in this field,” Hal Barron, Glaxo’s chief scientific officer, said in the statement.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":609652135,"gmtCreate":1638282221750,"gmtModify":1638282221750,"author":{"id":"3582025039109958","authorId":"3582025039109958","name":"SHUAT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3582025039109958","authorIdStr":"3582025039109958"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609652135","repostId":1157221915,"repostType":4,"repost":{"id":"1157221915","kind":"news","pubTimestamp":1638278781,"share":"https://www.laohu8.com/m/news/1157221915?lang=&edition=full","pubTime":"2021-11-30 21:26","market":"us","language":"en","title":"Glaxo Lures Top Pfizer Scientist to Lead Vaccines Research","url":"https://stock-news.laohu8.com/highlight/detail?id=1157221915","media":"Bloomberg","summary":"Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain positio","content":"<ul>\n <li>Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot</li>\n <li>Drugmaker is trying to regain position as top vaccine producer</li>\n</ul>\n<p>GlaxoSmithKline Plc&nbsp;lured a senior&nbsp;Pfizer Inc.&nbsp;scientist who helped develop the U.S. pharma company’s Covid shot to oversee vaccines research and development as it takes on increased competition in the field.</p>\n<p>Phil Dormitzer is set to join Glaxo as global head of vaccines R&amp;D, the British pharma company said in a statement Tuesday. As chief scientific officer of RNA and viral vaccines at Pfizer, he worked on respiratory syncytial virus and influenza shots, as well as the RNA-based Covid vaccine with BioNTech SE.</p>\n<p>Glaxo was the number-one producer of vaccines before the pandemic but failed to successfully develop its own Covid shot while Pfizer,Moderna Inc.&nbsp;and U.K. rival&nbsp;AstraZeneca Plc&nbsp;managed to do so. The pharma company is now seeking to capitalize on technologies such as messenger RNA and ensure it’s a dominant player beyond the pandemic.</p>\n<p>Activist investment firm Elliott Investment Management has been agitating for changes at the drugmaker since taking a multi-billion-dollar stake in the company and publicly disagreeing with some parts of its strategy.</p>\n<p>An experimental Covid vaccine Glaxo has been developing with Sanofi has suffered months of delays, but could become available next year if a late-stage trial is successful.</p>\n<p>Pfizer expects $36 billion in revenue from its Covid vaccine this year.</p>\n<p>Dormitzer’s appointment comes as Glaxo prepares for a separation in mid-2022 that will leave a standalone pharma and vaccines company. The new vaccines executive, who will be based in the Boston area, previously worked at Novartis AG, where he was involved in the Swiss drugmaker’s response to the H1N1 influenza pandemic, among other roles.</p>\n<p>“Phil’s scientific expertise and significant experience with key innovative technologies, such as mRNA, structure-based antigen design and synthetic biology, will be key to ensuring we remain a leader in this field,” Hal Barron, Glaxo’s chief scientific officer, said in the statement.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo Lures Top Pfizer Scientist to Lead Vaccines Research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo Lures Top Pfizer Scientist to Lead Vaccines Research\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain position as top vaccine producer\n\nGlaxoSmithKline Plc lured a senior Pfizer Inc. scientist who helped ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157221915","content_text":"Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain position as top vaccine producer\n\nGlaxoSmithKline Plc lured a senior Pfizer Inc. scientist who helped develop the U.S. pharma company’s Covid shot to oversee vaccines research and development as it takes on increased competition in the field.\nPhil Dormitzer is set to join Glaxo as global head of vaccines R&D, the British pharma company said in a statement Tuesday. As chief scientific officer of RNA and viral vaccines at Pfizer, he worked on respiratory syncytial virus and influenza shots, as well as the RNA-based Covid vaccine with BioNTech SE.\nGlaxo was the number-one producer of vaccines before the pandemic but failed to successfully develop its own Covid shot while Pfizer,Moderna Inc. and U.K. rival AstraZeneca Plc managed to do so. The pharma company is now seeking to capitalize on technologies such as messenger RNA and ensure it’s a dominant player beyond the pandemic.\nActivist investment firm Elliott Investment Management has been agitating for changes at the drugmaker since taking a multi-billion-dollar stake in the company and publicly disagreeing with some parts of its strategy.\nAn experimental Covid vaccine Glaxo has been developing with Sanofi has suffered months of delays, but could become available next year if a late-stage trial is successful.\nPfizer expects $36 billion in revenue from its Covid vaccine this year.\nDormitzer’s appointment comes as Glaxo prepares for a separation in mid-2022 that will leave a standalone pharma and vaccines company. The new vaccines executive, who will be based in the Boston area, previously worked at Novartis AG, where he was involved in the Swiss drugmaker’s response to the H1N1 influenza pandemic, among other roles.\n“Phil’s scientific expertise and significant experience with key innovative technologies, such as mRNA, structure-based antigen design and synthetic biology, will be key to ensuring we remain a leader in this field,” Hal Barron, Glaxo’s chief scientific officer, said in the statement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609621023,"gmtCreate":1638281193002,"gmtModify":1638281193168,"author":{"id":"4087798944081960","authorId":"4087798944081960","name":"Jeromelim","avatar":"https://static.tigerbbs.com/45cd82e500d76165963f39f22aa6230e","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087798944081960","authorIdStr":"4087798944081960"},"htmlText":"that’s positive thinking&nbsp;","listText":"that’s positive thinking&nbsp;","text":"that’s positive thinking","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609621023","repostId":1157221915,"repostType":4,"repost":{"id":"1157221915","kind":"news","pubTimestamp":1638278781,"share":"https://www.laohu8.com/m/news/1157221915?lang=&edition=full","pubTime":"2021-11-30 21:26","market":"us","language":"en","title":"Glaxo Lures Top Pfizer Scientist to Lead Vaccines Research","url":"https://stock-news.laohu8.com/highlight/detail?id=1157221915","media":"Bloomberg","summary":"Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain positio","content":"<ul>\n <li>Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot</li>\n <li>Drugmaker is trying to regain position as top vaccine producer</li>\n</ul>\n<p>GlaxoSmithKline Plc&nbsp;lured a senior&nbsp;Pfizer Inc.&nbsp;scientist who helped develop the U.S. pharma company’s Covid shot to oversee vaccines research and development as it takes on increased competition in the field.</p>\n<p>Phil Dormitzer is set to join Glaxo as global head of vaccines R&amp;D, the British pharma company said in a statement Tuesday. As chief scientific officer of RNA and viral vaccines at Pfizer, he worked on respiratory syncytial virus and influenza shots, as well as the RNA-based Covid vaccine with BioNTech SE.</p>\n<p>Glaxo was the number-one producer of vaccines before the pandemic but failed to successfully develop its own Covid shot while Pfizer,Moderna Inc.&nbsp;and U.K. rival&nbsp;AstraZeneca Plc&nbsp;managed to do so. The pharma company is now seeking to capitalize on technologies such as messenger RNA and ensure it’s a dominant player beyond the pandemic.</p>\n<p>Activist investment firm Elliott Investment Management has been agitating for changes at the drugmaker since taking a multi-billion-dollar stake in the company and publicly disagreeing with some parts of its strategy.</p>\n<p>An experimental Covid vaccine Glaxo has been developing with Sanofi has suffered months of delays, but could become available next year if a late-stage trial is successful.</p>\n<p>Pfizer expects $36 billion in revenue from its Covid vaccine this year.</p>\n<p>Dormitzer’s appointment comes as Glaxo prepares for a separation in mid-2022 that will leave a standalone pharma and vaccines company. The new vaccines executive, who will be based in the Boston area, previously worked at Novartis AG, where he was involved in the Swiss drugmaker’s response to the H1N1 influenza pandemic, among other roles.</p>\n<p>“Phil’s scientific expertise and significant experience with key innovative technologies, such as mRNA, structure-based antigen design and synthetic biology, will be key to ensuring we remain a leader in this field,” Hal Barron, Glaxo’s chief scientific officer, said in the statement.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo Lures Top Pfizer Scientist to Lead Vaccines Research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo Lures Top Pfizer Scientist to Lead Vaccines Research\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain position as top vaccine producer\n\nGlaxoSmithKline Plc lured a senior Pfizer Inc. scientist who helped ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157221915","content_text":"Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain position as top vaccine producer\n\nGlaxoSmithKline Plc lured a senior Pfizer Inc. scientist who helped develop the U.S. pharma company’s Covid shot to oversee vaccines research and development as it takes on increased competition in the field.\nPhil Dormitzer is set to join Glaxo as global head of vaccines R&D, the British pharma company said in a statement Tuesday. As chief scientific officer of RNA and viral vaccines at Pfizer, he worked on respiratory syncytial virus and influenza shots, as well as the RNA-based Covid vaccine with BioNTech SE.\nGlaxo was the number-one producer of vaccines before the pandemic but failed to successfully develop its own Covid shot while Pfizer,Moderna Inc. and U.K. rival AstraZeneca Plc managed to do so. The pharma company is now seeking to capitalize on technologies such as messenger RNA and ensure it’s a dominant player beyond the pandemic.\nActivist investment firm Elliott Investment Management has been agitating for changes at the drugmaker since taking a multi-billion-dollar stake in the company and publicly disagreeing with some parts of its strategy.\nAn experimental Covid vaccine Glaxo has been developing with Sanofi has suffered months of delays, but could become available next year if a late-stage trial is successful.\nPfizer expects $36 billion in revenue from its Covid vaccine this year.\nDormitzer’s appointment comes as Glaxo prepares for a separation in mid-2022 that will leave a standalone pharma and vaccines company. The new vaccines executive, who will be based in the Boston area, previously worked at Novartis AG, where he was involved in the Swiss drugmaker’s response to the H1N1 influenza pandemic, among other roles.\n“Phil’s scientific expertise and significant experience with key innovative technologies, such as mRNA, structure-based antigen design and synthetic biology, will be key to ensuring we remain a leader in this field,” Hal Barron, Glaxo’s chief scientific officer, said in the statement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":609661279,"gmtCreate":1638280145305,"gmtModify":1638280145543,"author":{"id":"3582072891665879","authorId":"3582072891665879","name":"Jimmyboy","avatar":"https://static.tigerbbs.com/cb9d5d497bceb3edaca216e9eeab3c22","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582072891665879","authorIdStr":"3582072891665879"},"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609661279","repostId":1157221915,"repostType":4,"repost":{"id":"1157221915","kind":"news","pubTimestamp":1638278781,"share":"https://www.laohu8.com/m/news/1157221915?lang=&edition=full","pubTime":"2021-11-30 21:26","market":"us","language":"en","title":"Glaxo Lures Top Pfizer Scientist to Lead Vaccines Research","url":"https://stock-news.laohu8.com/highlight/detail?id=1157221915","media":"Bloomberg","summary":"Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain positio","content":"<ul>\n <li>Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot</li>\n <li>Drugmaker is trying to regain position as top vaccine producer</li>\n</ul>\n<p>GlaxoSmithKline Plc&nbsp;lured a senior&nbsp;Pfizer Inc.&nbsp;scientist who helped develop the U.S. pharma company’s Covid shot to oversee vaccines research and development as it takes on increased competition in the field.</p>\n<p>Phil Dormitzer is set to join Glaxo as global head of vaccines R&amp;D, the British pharma company said in a statement Tuesday. As chief scientific officer of RNA and viral vaccines at Pfizer, he worked on respiratory syncytial virus and influenza shots, as well as the RNA-based Covid vaccine with BioNTech SE.</p>\n<p>Glaxo was the number-one producer of vaccines before the pandemic but failed to successfully develop its own Covid shot while Pfizer,Moderna Inc.&nbsp;and U.K. rival&nbsp;AstraZeneca Plc&nbsp;managed to do so. The pharma company is now seeking to capitalize on technologies such as messenger RNA and ensure it’s a dominant player beyond the pandemic.</p>\n<p>Activist investment firm Elliott Investment Management has been agitating for changes at the drugmaker since taking a multi-billion-dollar stake in the company and publicly disagreeing with some parts of its strategy.</p>\n<p>An experimental Covid vaccine Glaxo has been developing with Sanofi has suffered months of delays, but could become available next year if a late-stage trial is successful.</p>\n<p>Pfizer expects $36 billion in revenue from its Covid vaccine this year.</p>\n<p>Dormitzer’s appointment comes as Glaxo prepares for a separation in mid-2022 that will leave a standalone pharma and vaccines company. The new vaccines executive, who will be based in the Boston area, previously worked at Novartis AG, where he was involved in the Swiss drugmaker’s response to the H1N1 influenza pandemic, among other roles.</p>\n<p>“Phil’s scientific expertise and significant experience with key innovative technologies, such as mRNA, structure-based antigen design and synthetic biology, will be key to ensuring we remain a leader in this field,” Hal Barron, Glaxo’s chief scientific officer, said in the statement.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo Lures Top Pfizer Scientist to Lead Vaccines Research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo Lures Top Pfizer Scientist to Lead Vaccines Research\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain position as top vaccine producer\n\nGlaxoSmithKline Plc lured a senior Pfizer Inc. scientist who helped ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-30/glaxo-lures-top-pfizer-scientist-to-lead-vaccines-research?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157221915","content_text":"Phil Dormitzer helped develop Pfizer and BioNTech’s Covid shot\nDrugmaker is trying to regain position as top vaccine producer\n\nGlaxoSmithKline Plc lured a senior Pfizer Inc. scientist who helped develop the U.S. pharma company’s Covid shot to oversee vaccines research and development as it takes on increased competition in the field.\nPhil Dormitzer is set to join Glaxo as global head of vaccines R&D, the British pharma company said in a statement Tuesday. As chief scientific officer of RNA and viral vaccines at Pfizer, he worked on respiratory syncytial virus and influenza shots, as well as the RNA-based Covid vaccine with BioNTech SE.\nGlaxo was the number-one producer of vaccines before the pandemic but failed to successfully develop its own Covid shot while Pfizer,Moderna Inc. and U.K. rival AstraZeneca Plc managed to do so. The pharma company is now seeking to capitalize on technologies such as messenger RNA and ensure it’s a dominant player beyond the pandemic.\nActivist investment firm Elliott Investment Management has been agitating for changes at the drugmaker since taking a multi-billion-dollar stake in the company and publicly disagreeing with some parts of its strategy.\nAn experimental Covid vaccine Glaxo has been developing with Sanofi has suffered months of delays, but could become available next year if a late-stage trial is successful.\nPfizer expects $36 billion in revenue from its Covid vaccine this year.\nDormitzer’s appointment comes as Glaxo prepares for a separation in mid-2022 that will leave a standalone pharma and vaccines company. The new vaccines executive, who will be based in the Boston area, previously worked at Novartis AG, where he was involved in the Swiss drugmaker’s response to the H1N1 influenza pandemic, among other roles.\n“Phil’s scientific expertise and significant experience with key innovative technologies, such as mRNA, structure-based antigen design and synthetic biology, will be key to ensuring we remain a leader in this field,” Hal Barron, Glaxo’s chief scientific officer, said in the statement.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":58,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157221915"}